A blended vial containing both CJC-1295 (No-DAC) and Ipamorelin poses a slightly different handling question than a single-peptide vial. Two distinct molecules are lyophilized together, and both need to survive reconstitution and storage as a unit rather than as separate, independently timed compounds.
Reconstituting a two-peptide vial
The reconstitution itself follows the same general logic used for any lyophilized peptide: diluent is introduced slowly down the interior wall of the vial rather than injected directly onto the freeze-dried cake, which reduces turbulence and mechanical stress on both peptides at once. Because CJC-1295 and Ipamorelin have different molecular weights, a researcher documenting a reconstitution should record diluent volume against the combined peptide mass listed on the vial, not against either compound individually, so downstream concentration calculations stay consistent across the whole solution. The general step-by-step procedure is covered in the lyophilized peptide reconstitution protocol.
Storing the reconstituted solution
After reconstitution, the blend is handled like most short-chain research peptides in solution: refrigeration in the 2-8°C range for near-term work, protection from light, and avoidance of repeated warm-to-cold cycling, all of which accelerate hydrolysis and aggregation in peptide solutions generally. Because the vial holds two peptides rather than one, any freeze-thaw event affects both simultaneously — there is no way to isolate one component if the other degrades. Aliquoting the reconstituted stock into single-use portions immediately after mixing is the most common way labs sidestep this, since it removes the need to repeatedly access one working vial over days or weeks.
Handling shipping-related temperature exposure
Even before reconstitution, the lyophilized blend should arrive having been kept within a reasonable temperature range in transit; briefly elevated shipping temperatures are generally less damaging to a freeze-dried powder than to a reconstituted solution, but a vial that has visibly been exposed to prolonged heat is worth flagging rather than assuming intact potency on arrival. Once reconstituted, that margin for tolerance narrows considerably for both peptides.
Why the two components don't necessarily age at the same rate
CJC-1295 (No-DAC) and Ipamorelin are structurally unrelated peptides, and in solution they do not necessarily degrade at exactly the same rate — a detail worth tracking in comparative or longitudinal assay designs rather than single-timepoint work. This is also why documenting reconstitution date and storage conditions matters more for a blend than for a single peptide: a shift in one component's apparent behavior during an assay could reflect a compound-specific storage effect rather than a biological result.
Confirming what's actually in the vial before storage even begins
None of the above matters if the starting lyophilized material wasn't well characterized. Each production batch is verified for identity and purity of both components before shipment, and that data — not just the vial label — is what a lab should keep on file alongside its own reconstitution and storage log. See CJC-1295 & Ipamorelin purity testing for how that verification is performed.
Product page: CJC-1295 (No-DAC) & Ipamorelin research blend.
Research Use Only. Supplied strictly for laboratory research and development — not for human or veterinary use, consumption, or any therapeutic or diagnostic purpose. This article is research education, not usage guidance.